LABD - Direxion Daily S&P Biotech Bear 3X ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
22.50
-1.51 (-6.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close24.01
Open23.75
Bid0.00 x 1400
Ask0.00 x 800
Day's Range22.50 - 23.98
52 Week Range21.35 - 375.00
Volume3,166,328
Avg. Volume2,612,791
Net Assets105.06M
NAV22.47
PE Ratio (TTM)N/A
Yield1.38%
YTD Return-47.13%
Beta (3Y Monthly)-5.22
Expense Ratio (net)1.00%
Inception Date2015-05-28
Trade prices are not sourced from all markets
  • Benzingalast month

    This Biotech ETF Is Soaring, But A Bearish Friend Lures Traders

    Biotechnology stocks and the related exchange traded funds are off to sizzling starts in 2019. The soaring start to 2019 by the equal-weight S&P Biotechnology Select Industry Index is lifting the fortunes of the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU). LABU, one of the largest leveraged biotechnology ETFs, is up more than 45 percent year-to-date, easily making it ne of Direxion's best-performing leveraged bullish ETFs in the month of January.

  • 7 Inverse ETFs That Soared More Than 70% in Q4
    Zacks2 months ago

    7 Inverse ETFs That Soared More Than 70% in Q4

    The myriad woes have resulted in huge demand for inverse or leveraged inverse ETFs for investors seeking to make big gains in a short span.

  • Benzinga3 months ago

    The Time Could Be Right For This Biotech ETF

    Biotechnology stocks and exchange traded funds have been slumping since last week's midterm elections and that could be an ominous sign. Ongoing weakness for the equal-weight S&P Biotechnology Select Industry Index benefits the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD). LABD, one of the most heavily traded leveraged biotechnology ETFs, aims to deliver triple the daily inverse returns of the S&P Biotechnology Select Industry Index.

  • 7 Leveraged/Inverse ETFs Off to a Strong Start in October
    Zacks4 months ago

    7 Leveraged/Inverse ETFs Off to a Strong Start in October

    The leveraged and inverse leveraged space has grabbed investors' attention at the start of October in order to magnify returns on quick market turns.

  • How the Biotech Sector Has Fared this Year
    Market Realist6 months ago

    How the Biotech Sector Has Fared this Year

    Usually, when investors add biotechnology stocks to their portfolios, they feel confident about risk. When they want to reduce risk, biotech names are the first to go. LABU (3X Biotech Bull) and LABD (3X Biotech Bear) can help you stay risk-on or risk-off.

  • Benzinga7 months ago

    Exploring The Leveraged ETF Trade Heading Into Earnings Season

    Many institutional traders use multi-faceted strategies that involve several different instruments when trading around an earnings report. Among the most common hedging tools used by institutions are leveraged ETFs, which are built to deliver multiples (or inverse multiples) on a given index. “They aren’t meant to be held for more than a few days at a time,” Sylvia Jablonski, managing director of leveraged ETF provider Direxion ETFs said.

  • Benzinga11 months ago

    For Now, Traders Endorse Biotech Rally

    Among leveraged and inverse biotechnology exchange-traded funds, the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU ) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD ) are the dominant ...

  • Direxion Announces Reverse Splits of Five ETFs
    PR Newswirelast year

    Direxion Announces Reverse Splits of Five ETFs

    NEW YORK , Feb. 28, 2018 /PRNewswire/ -- Direxion has announced it will execute a reverse split of the issued and outstanding shares of the Direxion Daily Technology Bear 3X Shares, Direxion Daily Energy ...